BW
ADCY 5/6 (F1052) polyclonal Antibody | BS2208
- SKU:
- BW-BS2208
- Availability:
- Usually ships in 5 working days
Description
ADCY 5/6 (F1052) polyclonal Antibody | BS2208 | Gentaur UK, US & Europe Distribution
Host: Rabbit
Reactivity: Human,Mouse,Rat
Application: WB IHC IF
Application Range: WB: 1:500~1:1000 IHC: 1:50~1:200 IF: 1:50~1:200
Background: A cyclase V, also known as ADCY5, is a 1,261 amino acid Adenylyl cyclase that localizes to cellular membranes and contains two guanylate cyclase domains. Similar to other A cyclase proteins, A cyclase V uses magnesium as a cofactor to catalyze the conversion of ATP to cAMP. A cyclase VI, also known as ADCY6 (adenylate cyclase type 6), is a 1,168 amino acid A cyclase that localizes to the membrane and contains two guanylate cyclase domains. Using magnesium as a cofactor, A cyclase VI functions as a calcium-inhibitable A cyclase that catalyzes the conversion of ATP to 3',5'-cyclic AMP and diphosphate and plays a role in a variety of events throughout the body. Multiple isoforms of A cyclase VI exist due to alternative splicing events.
Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
Specificity: ADCY 5/6 (F1052) polyclonal Antibody detects endogenous levels of Adenylate cyclase type 5 and Adenylate cyclase type 6 protein.
Molecular Weight: ~ 130, 139 kDa
Note: For research use only, not for use in diagnostic procedure.
Alternative Names: A cyclase V; A cyclase VI; Adenylate cyclase type 5; ATP pyrophosphate-lyase 5; Adenylate cyclase type V; Adenylyl cyclase 5; ADCY5; Adenylate cyclase type 6; ATP pyrophosphate-lyase 6; Adenylate cyclase type VI; Adenylyl cyclase 6; Ca (2+) -inhibitable adenylyl cyclase; ADCY6; KIAA0422
Immunogen: Synthetic peptide, corresponding to amino acids 1111-1160 of Human ADCY 5
Conjugate: Unconjugated
Modification: Unmodification
Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .
Pathway: